Search

Search Results

• CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

  Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi

  e2010017

  2010-06-18

  https://doi.org/10.4084/mjhid.2010.017

  1706

  PDF: 747

  HTML: 2347

• BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN

  Maria Teresa Voso, Giulia Falconi, Dr. Fabiani

  e2023055

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.055

  1827

  PDF: 993

  HTML: 147

• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

  Judit Demeter, Julia Weisinger, Zsolt Nagy

  e2021022

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.022

  1438

  PDF: 497

  HTML: 235

• ANORECTAL COMPLICATIONS DURING NEUTROPENIC PERIOD IN PATIENTS WITH HEMATOLOGIC DISEASES

  Soner Solmaz

  e2016019

  2016-03-01

  https://doi.org/10.4084/mjhid.2016.019

  3051

  PDF: 986

  HTML: 1570

• COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025050

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.050

  748

  PDF: 521

  HTML: 56

• Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

  Monica Carpenedo, Dr, Dr, Dr

  e2023021

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.021

  1215

  PDF: 1109

  HTML: 704

• Leukocyte derived chemotaxin 2 (ALECT2) amyloidosis

  Uday P Kulkarni, Anna Valson, Anila Korula, Vikram Mathews

  e2015043

  2015-07-01

  https://doi.org/10.4084/mjhid.2015.043

  1608

  PDF: 785

  HTML: 1311

• SAFETY OF BRONCHOALVEOLAR LAVAGE IN HEMATOLOGICAL PATIENTS WITH THROMBOCYTOPENIA – A RETROSPECTIVE COHORT STUDY

  Ivan GUR, Roei Tounek, Yaniv Dotan, Elite Vainer Evgrafov, Stav Rakedzon, Eyal Fuchs

  e2024006

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.006

  1208

  PDF: 1305

  HTML: 205

• THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE

  Lucrezia Laterza, Gianenrico Rizzatti, Eleonora Gaetani, Patrizia Chiusolo, Antonio Gasbarrini

  e2016025

  2016-05-01

  https://doi.org/10.4084/mjhid.2016.025

  6371

  PDF: 2142

  HTML: 14031

  Untitled: 207

  figure: 191

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3301

  PDF: 1231

  HTML: 3475

• Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.

  Maria Dmitrievna Sanatko

  e2012047

  2012-06-30

  https://doi.org/10.4084/mjhid.2012.047

  2397

  PDF: 881

  HTML: 687

  Untitled: 161

• PROPHYLAXIS OF MALARIA

  Eli Schwartz

  e2012045

  2012-06-29

  https://doi.org/10.4084/mjhid.2012.045

  3043

  PDF: 1046

  HTML: 17842

  Figures SChwartz: 172

• PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA

  Roberto Stasi, Lian Wea Chia, Pallavi Kalkur, Robert Lown, Muriel S. Shannon

  e2009023

  https://doi.org/10.4084/mjhid.2009.023

  872

  PDF: 600

  HTML: 1458

• The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients

  Shuku Sato

  e2025070

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.070

  1231

  PDF: 418

  HTML: 98

• AN OBSERVATIONAL STUDY OF THE EFFECT OF HEMOGLOBINOPATHY, ALPHA THALASSEMIA AND HEMOGLOBIN E ON P. VIVAX PARASITEMIA

  Suparak Para, Puncharee Mungkalasut, Makamas Chanda, Issarang Nuchprayoon, Srivicha Krundsood, Chalisa Louicharoen Cheepsunthorn

  e2018015

  2018-02-16

  https://doi.org/10.4084/mjhid.2018.015

  2841

  PDF: 910

  HTML: 381

  Distribution of malaria patient cohort along Thailand and borders during 2011-2012: 201

• VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis

  Alexandros Makis, Sophia Tsabouri, Paraskevi Karagouni, Maria Rogalidou, Irene Sionti, Nikolaos Chaliasos

  e2017011

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.011

  2822

  PDF: 800

  HTML: 1531

• Transfusion associated peak in Hb HPLC chromatogram – a case report

  Sonal Jain, Jasmita Dass, Hara Prasad Pati

  e2012006

  2012-01-21

  https://doi.org/10.4084/mjhid.2012.006

  1090

  PDF: 780

  HTML: 2746

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2499

  PDF: 797

  HTML: 1738

• EVOLUTION OF HEMOGLOBINOPATHY PREVENTION IN AFRICA

  Slaheddine Fattoum

  e2009005

  2009-10-27

  1061

  PDF: 429

  HTML: 15035

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  1982

  PDF: 1670

  HTML: 133

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1535

  PDF: 1174

  HTML: 290

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1428

  PDF: 745

  HTML: 308

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2242

  PDF: 1254

  HTML: 352

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2282

  PDF: 2168

  HTML: 2438

• VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE

  Ashraf Tawfik Soliman

  e2013057

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.057

  2760

  PDF: 1093

  HTML: 2583

• IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS

  Efterpi Kostareli, Maria Gounari, Andreas Agathangelidis, Kostas Stamatopoulos

  e2012052

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.052

  3099

  PDF: 886

  HTML: 7172

  Kost Fig1: 195

  Kost Fig 2: 187

  Kost Fig3: 186

  Kost Fig 4: 199

  Kost Fig5: 194

  Kost fig 6: 181

• SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib

  Matteo Molica

  e2024079

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.079

  961

  PDF: 524

  HTML: 215

• Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major

  Kun Yang

  e2023053

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.053

  729

  PDF: 569

  HTML: 170

• TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY

  Agustin Avilès, Maria-Jesus Nambo, Natividad Neri

  e2018006

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.006

  3592

  PDF: 1086

  HTML: 880

• Skin Manifestations associated with Mantle cell Lymphoma: a case report

  avinash kumar singh, Gaurav Dixit, sanjeev sharma, rajni yadav, Narendra agrawaal, chitra sarkar, pravas mishra, Tulika seth, manoranjan mahapatra, Renu saxena

  e2013020

  2013-02-24

  https://doi.org/10.4084/mjhid.2013.020

  1578

  PDF: 772

  HTML: 2153

  Untitled: 228

  Untitled: 200

  Untitled: 197

  Untitled: 208

  Untitled: 202

• Long-term persistence of dysplastic features in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide

  Enrico Santinelli, Maria Rosaria Pascale, Luca Guarnera, Arianna Savi, Flavia Mallegni, Carmelo Gurnari, Luca Maurillo, Maria Teresa Voso, Susanna Fenu

  e2025038

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.038

  1055

  PDF: 753

  HTML: 90

• Hyperhemolytic Syndrome complicating a Delayed Hemolytic Transfusion Reaction due to anti-P1 alloimmunization, in a pregnant woman with HbO-Arab?-thalassemia

  Zoe Bezirgiannidou, Anna Christoforidou, Eftychia Kontekaki, Athanasios Anastasiadis, Spyros Papamichos, Helen Menexidou, Dimitrios Margaritis, George Martinis, Elpidoforos Mandadakis

  e2016053

  2016-10-18

  https://doi.org/10.4084/mjhid.2016.053

  3218

  PDF: 914

  HTML: 1282

  Figure 1: 164

• THE UTILITY OF BLOOD AND BONE MARROW FILMS AND TREPHINE BIOPSY SECTIONS IN THE DIAGNOSIS OF PARASITIC INFECTIONS

  Clare Miller, Barbara Bain

  e2015039

  2015-05-26

  https://doi.org/10.4084/mjhid.2015.039

  1787

  PDF: 1162

  HTML: 21424

• SHORT TERM ADVANTAGES OF A PUBLIC-PRIVATE PARTNERSHIP FOR TUBERCULOSIS IN GUINEA BISSAU: REDUCTION OF MORTALITY AND INCREASED DIAGNOSTIC CAPACITY

  Fina Vieira, Mamadu Saliu Sanha, Fabio Riccardi, Raffaella Colombatti

  e2014049

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.049

  1431

  PDF: 922

  HTML: 1283

  Untitled: 181

• EFFECT OF CIS ACTING POTENTIAL REGULATORS IN THE ß GLOBIN GENE CLUSTER ON THE PRODUCTION OF HBF IN THALASSEMIA PATIENTS

  Anita Nadkarni

  e2013012

  2013-02-16

  https://doi.org/10.4084/mjhid.2013.012

  1154

  PDF: 605

  HTML: 3341

• OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION

  Rafael Rojas, José R. Molina, Isidro Jarque, Miguel A. Sanz

  e2012011

  2012-02-10

  https://doi.org/10.4084/mjhid.2012.011

  1133

  PDF: 550

  HTML: 1699

  Figures: 175

  Fifures Sanz: 181

  tables Sanz: 184

  Untitled: 183

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1073

  PDF: 701

  HTML: 351

• Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients

  Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini, Beatrice Casadei, Francesca Bonifazi, Pier Luigi Zinzani

  e2024004

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.004

  1464

  PDF: 1416

  HTML: 194

• Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission

  Beatrice Borsellino, Arianna Savi, Maria Rosaria Pascale, Elisa Meddi, Antonio Cristiano, TIZIANA OTTONE, Maria Cristina Rapanotti, Mariadomenica Divona, SERENA TRAVAGLINI, Enrico Attardi, Elisa Buzzatti, Francesco Buccisano, Maria Teresa Voso

  e2022058

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.058

  1697

  PDF: 788

  HTML: 264

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5296

  PDF: 1948

  HTML: 1366

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  4035

  PDF: 1535

  HTML: 9192

  Untitled: 284

  Untitled: 192

  Untitled: 176

  Untitled: 170

  Untitled: 194

  Untitled: 349

• CLASSIC KSHV/HHV-8-POSITIVE PRIMARY EFFUSION LYMPHOMA (PEL): A SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS

  Ilaria Cozzi, Giovanni Rossi, Emma Rullo, Valeria Ascoli

  e2022020

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.020

  1584

  PDF: 969

  HTML: 346

• Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance

  Holly Lee, Peter Duggan, Ernesta Paola Neri, Jason Tay, Victor Jimenez Zepeda

  e2019007

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.007

  2227

  PDF: 1187

  HTML: 343

• ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY

  Farida El-Rashedy, Mahmoud Ahmed El-Hawy, Sally El Hefnawy, Mona Mohammed

  e2017026

  2017-04-15

  https://doi.org/10.4084/mjhid.2017.026

  2529

  PDF: 922

  HTML: 1302

  Untitled: 233

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2048

  PDF: 774

  HTML: 3118

• Primary Pancreatic Lymphoma in a Patient with Maturity Onset Diabetes of the Young type 3

  Valentina Bozzoli, Maria Chiara Tisi, Luigi Pianese, Stefano Tumini, Vittoria Rufini, Maria Lucia Calcagni, Dario Pitocco, Alberto Larghi, Luigi Maria Larocca, Giuseppina Massini, Luciana Teofili, Francesco D'Alò, Stefan Hohaus

  e2012005

  2012-01-18

  https://doi.org/10.4084/mjhid.2012.005

  1548

  PDF: 719

  HTML: 979